ArticleJournal of bacteriology2022
Investigation of the Mechanism and Chemistry Underlying Staphylococcus aureus
Article in Journal of bacteriology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Differential Metabolite Production Underlies Disruption of the Cystic Fibrosis Airway Microbiota by Pathogens.bioRxiv : the preprint server for biology · 2026Article
- Paving the way or sharing goods?-Interactions between pairs ofFrontiers in microbiology · 2026Article
- Review
- Modeling reciprocal adaptation ofBiofilm · 2025Article
- Development of a tri-species wound model for studying fungal-bacterial interactions and antimicrobial therapies.Biofilm · 2025Article
- Evaluation of early bacterial adhesion on CAD/CAM dental materials: an in situ study.Odontology · 2025Article
- Polymicrobial infection in cystic fibrosis and future perspectives for improving Mycobacterium abscessus drug discovery.npj antimicrobials and resistance · 2024Review
- Understanding and treating diabetic foot ulcers: Insights into the role of cutaneous microbiota and innovative therapies.Skin health and disease · 2024Review
- Escherichia coli has an undiscovered ability to inhibit the growth of both Gram-negative and Gram-positive bacteria.Scientific reports · 2024Article
- Experimentally evolvedMicrobiology (Reading, England) · 2024Article
- The type IV pilus chemoreceptor PilJ controls chemotaxis of one bacterial species towards another.PLoS biology · 2024Article
- Swarming ofBiophysics reviews · 2023Review
- Alterations in Antibiotic Susceptibility ofInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Pseudomonas aeruginosa inhibits or eradicates Staphylococcus aureus in most in vitro settings. Nonetheless, P. aeruginosa and S. aureus are commonly isolated from chronically infected, nonhealing wounds and lungs of people with cystic fibrosis (CF). Therefore, we hypothesized that S. aureus could protect itself from P. aeruginosa through glucose-derived metabolites, such as small organic acids, preventing it from being eradicated. This
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.